The US National Institute of Allergy and Infectious Diseases (National Institute of Allergy & Infectious Diseases (NIAID)) announced that HVTN 702, a large-scale HIV vaccine efficacy trial of a canary pox-based vaccine candidate, has been stopped following an...
Seqirus announced the U.S. FDA has approved Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1). Audenz is the first-ever adjuvanted, cell-based influenza vaccine designed to...
SCYNEXIS announced positive results from its second interim efficacy analysis of the ongoing Phase 3 open-label FURI study. The study is evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and invasive fungal...
Navigen announced that the U.S. FDA has cleared its Investigational New Drug application (IND) for the initiation of a Phase I study in healthy volunteers to test the safety, tolerability, and pharmacokinetics of its D-Peptide HIV entry inhibitor, CPT31. Results from...
ViiV Healthcare announced it has submitted an NDA to the U.S. FDA seeking approval of fostemsavir for use in combination with other antiretroviral agents in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are unable to form a...
Emergent BioSolutions presented updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate across a series of dosing regimens....
